<DOC>
	<DOCNO>NCT02318836</DOCNO>
	<brief_summary>This Phase 1 , open-label , parallel-group , single-dose study lofexidine 6 adult subject mild hepatic impairment ( Child Pugh score 5 6 ) , 6 adult subject moderate hepatic impairment ( Child Pugh score 7 9 ) , 6 adult subject severe hepatic impairment ( Child Pugh score 10 15 ) , 6 control subject normal hepatic function mean age , body mass index ( BMI ) , gender distribution target similar impaired hepatic function cohort .</brief_summary>
	<brief_title>Single-Dose Pharmacokinetics Safety Oral Lofexidine Hepatically-Impaired Subjects</brief_title>
	<detailed_description>This Phase 1 , open-label , parallel-group , single-dose study lofexidine 6 adult subject mild hepatic impairment ( Child Pugh score 5 6 ) , 6 adult subject moderate hepatic impairment ( Child Pugh score 7 9 ) , 6 adult subject severe hepatic impairment ( Child Pugh score 10 15 ) , 6 control subject normal hepatic function mean age , body mass index ( BMI ) , gender distribution target similar impaired hepatic function cohort . Subjects confine inpatient facility even dose 144 hour dose . Subjects successfully complete screen report inpatient facility appropriate time even study drug administration ( Day 1 ) ensure minimum 10 hour fast . The next morning ( Day 1 ) still fast , subject receive single , oral dose 400 µg lofexidine HCl ( two 200 µg tablet ) . Blood sample collect PK analysis multiple time point next 144 hour ( Day 7 ) . Pooled urine sample collect 0 3 hour , 3 6 hour , 6 12 hour , 12 24 hour , 24 48 hour , 48 96 hour , 96 120 hour 120 144 hour post-dose . Safety assess record adverse event ( AEs ) , measure vital sign ( blood pressure pulse rate ) clinical laboratory test ( chemistry , hematology , urinalysis ) , record 12 lead safety Holter electrocardiogram ( ECGs ) , perform physical exam .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Site evaluate subject criterion detail , include : 1 . Between age 18 65 year enrollment BMI 19 38 kg/m2 , inclusive . 2 . Subject eligible enter study : Matched control subject : normal hepatic function free clinically significant illness disease , medical history , physical examination , laboratory result , test consistent health , determine Investigator . Subject mild hepatic impairment : ChildPugh hepatic dysfunction stag system score 56 Points ( Stage A ) medical history , physical examination , laboratory result , test consistent hepatic impairment , determine Investigator . Subject moderate hepatic impairment : ChildPugh hepatic dysfunction stag system score 7 9 Points ( Stage B ) medical history , physical examination , laboratory result , test consistent hepatic impairment , determine Investigator . Subject severe hepatic impairment : ChildPugh hepatic dysfunction stag system score 1015 Points ( Stage C ) medical history , physical examination , laboratory result , test consistent hepatic impairment , determine Investigator . Site evaluate subject criterion detail , include : 1 . The matched control subject history clinically significant disease , include cardiovascular , gastrointestinal ( GI ) , renal , hepatic , pulmonary , endocrine , hematologic , vascular , immunologic , metabolic , collagen disease hepaticallyimpaired subject history clinically significant disease include cardiovascular , GI , renal , pulmonary , endocrine , hematologic , vascular , immunologic , metabolic , collagen disease . 2 . Abnormal cardiovascular exam Screening , include follow : clinically significant abnormal ECG ( e.g. , second third degree heart block , uncontrolled arrhythmia , QTcF ( Fridericia 's correction ) interval &gt; 450 msec male &gt; 470 msec female ) . heart rate &lt; 45 bpm symptomatic bradycardia ; systolic blood pressure &lt; 90 mmHg symptomatic hypotension ; blood pressure &gt; 160/100 mmHg ; prior history myocardial infarction . 3 . Subjects hepatic impairment eligible participate study follow exclusion criterion also apply : Significant bleed diathesis esophageal bleed within last 8 week . Evidence hepatic function deterioration within last 4 week indicate liver transaminase , alkaline phosphatase , gammaglutamyl transpeptidase ≥50 % worsen serum bilirubin prothrombin time . History surgical portosystemic shunt . Prothrombin time &gt; 18 second .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hepatic , hepatic impairment , lofexidine</keyword>
</DOC>